Herpes simplex-1 (HSV-1) is a sporadic cause of viral encephalitis. We have previously demonstrated that corneal HSV inoculation markedly activates the hypothalamo-pituitary-adrenal (HPA) axis. This activation depends on host derived brain interleukine-1 and was resistant to pretreatment with dexamethasone (dex), possibly because immune factors such as pro-inflammatory cytokines can modify the binding capacity of glucocorticoids in the hippocampus. In the present study, we examined whether resistance of the HPA axis activation following intracerebral HSV-1 infection to dex-induced suppression is associated with modifications in hippocampal or pituitary glucocorticoids (GC) receptors or GC receptors in cultured astrocytes. Male rats were injected intracerebroventricularly with purified HSV-1 or vehicle. 48 h later, dex or vehicle was injected intraperitoneally. Rats were sacrificed 3.5 h later. ACTH and corticosterone (CS) were measured in the serum. Specific binding of 3H-dex was measured in the cytosolic fraction of the hippocampus and the pituitary. Dex failed to reduce ACTH and CS responses to HSV-1 infection. In contrast, dex significantly reduced ACTH and CS responses to acoustic neural stimuli. Infection with HSV-1 markedly reduced the hippocampal maximal specific binding of dex with no effect on the dissociation constant (Kd) values. HSV-1 had no effect on the binding of dex in the pituitary. Infection of cultured astrocytes with HSV-1 also reduced the maximal specific binding of dex, but increased the Kd value. The results suggest that HSV-1 induced GC resistance may be mediated by downregulation of GC receptors in hippocampal tissue. These results may clarify a mechanism responsible for GC resistance following immune challenges.

Antoni FA: Hypothalamic control of adrenocorticotropin secretion: advances since the discovery of 41-residue corticotrophin-releasing factor. Endocr Rev 1986;7:351–378.
Whitnall MH: Regulation of the hypothalamic corticotrophin-releasing hormone neurosecretory system. Prog Neurobiol 1993;40:573–629.
Turnbull AV, Rivier CL: Regulation of the hypothalamic-pituitary-adrenal axis by cytokines: actions and mechanisms of action. Physiol Rev 1999;79:1–71.
Silverman MN, Pearce BD, Biron CA, Miller AH: Immune modulation of the hypothalamic-pituitary-adrenal (HPA) axis during viral infection. Viral Immunol 2005;18:41–78.
Feldman S, Conforti N, Weidenfeld J: Limbic pathways and hypothalamic neurotransmitters mediating adrenocortical responses to neural stimuli. Neurosci Biobehav Rev 1995;19:235–240.
Feldman S, Weidenfeld J: Neural mechanisms involved in the corticosteroid feedback effects on the hypothalamo-pituitary-adreno-cortical axis. Prog Neurobiol 1995;45:129–141.
De Kloet Er, Oitzl MS, Joels M: Functional implication of brain corticosteroid receptor diversity. Cell Mol Neurobiol 1993;13:433–455.
Herman JP: Regulation of the adrenocorticosteroid receptor mRNA expression in the central nervous system. Cell and Mol Neurobiol 1993;13:349–372.
Schaaf MJM, Cidlowski JA: Molecular mechanisms of glucocorticoid action and resistance. J Seroid Biochem Mol Biol 2003;83:37–48.
Pariante CM, Miller AH: Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biol Psychiatry 2001;49:391–404.
Cole MA, Kim PJ, Kalman BA, Spencer RL: Dexamethasone suppression of corticosteroid secretion: evaluation of the site of action by receptor measures and functional studies. Psychoneuroendocrinology 2000;25:151–167.
Sapolsky RM, Krey LC, McEwen BS: Glucocorticoid sensitive hippocampal neurons are involved in terminating the adrenocortical stress response. Proc Natl Acad Sci USA 1984;81:6174–6177.
Jacobson I, Sapolsky R: The role of the hippocampus in feedback regulation of the hypothalamic-pituitary-adrenocortical axis. Endocr Rev 1991;12:118–134.
Miller AH, Pariante CM, Pearce BD: Effects of cytokines on glucocorticoid receptor expression and function: glucocorticoid resistance and relevance to depression. Adv Exp Med Biol 1999;461:107–116.
De Kloet Er, Oitzl MS, Schobitz B: Cytokines and the brain corticosteroid receptor balance: relevance to pathophysiology of neuroendocrine-immune communication. Psyconeuroendocrinology 1994;19:121–134.
Pariante CM, Pearce BD, Pisell TL, et al: The proinflammatory cytokine, interleukin-I alpha, reduces glucocorticoid receptor translocation and function. Endocrinol 1999;140:4359–4366.
Weidenfeld J, Abrasmsky O, Ovadia H: Effect of interleukin-1 on ACTH and corticosterone secretion in dexamethasone and adrenalectomized pretreated male rats. Neuroendocrinology 1989;50:650–654.
Schobitz B, Sutanto W, Carey MP, Holsboer F, de-Kloet ER: Endotoxin and interleukin-1 decrease the affinity of hippocampal mineralocorticoid (type I) receptor in parallel to activation of the hypothalamic-pituitary-adrenal axis. Neuroendocrinology 1994;60:124–133.
Weidenfeld J, Yirmiya R: Effects of bacterial endotoxin on the glucocorticoid feedback regulation of adrenocortical response to stress. Neuroimmunomodulation 1996;3:352–357.
Ben-Hur T, Asher Y, Tabor E, Darai G, Becker Y: HSV-1 virulence for mice by the intracerebral route is encoded by the Bam HI-L DNA fragment containing the cell fusion gene. Arch Virol 1987;96:117–122.
Chou J, Kern ER, Whitley RJ, Roizman B: Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture. Science 1990;250:1262–1266.
Ben-Hur T, Conforti N, Itzik A, Weidenfeld J: Effects of HSV-1 a neurotropic virus on the hypothalamic-pituitary-adrenocortical axis in rats. Brain Res.1995;702:17–22.
Ben-Hur T, Rosenthal J, Itzik A, Weidenfeld J: Adrenocortical activation by herpes virus: involvement of IL-1 beta and central noradrenergic system. Neuroreport 1996;7:927–931.
Ben-Hur T, Cialic R, Itzik A, Barak O, Yirmiya R, Weidenfeld J: A novel permissive role for glucocorticoids in induction of febrile and behavioral signs of experimental herpes simplex virus encephalitis. Neuroscience 2001;108:119–127.
Ben-Hur T, Cialic R, Itzik A, Yirmiya R, Weidenfeld J: Acute effects of purified and UV-inactivated herpes simplex virus type 1 on the hypothalamo-pituitary-adrenocortical axis. Neuroendocrinology 2001;74:160–166.
Pellegrino LJ, Cushman AJ: A Stereotaxic Atlas of the Brain. New York, Plenum, 1981.
Weidenfeld J, Feldman S: Glucocorticoid feedback regulation of adrenocortical response to neural stimuli: role of CRF-41 and corticosteroid type I and II receptors. Neuroendocrinology 1993;58:49–56.
O’Donnell D, Francis D, Weaver S, Meaney MJ: Effects of adrenalectomy and corticosterone replacement on glucocorticoid receptor levels in rat brain tissue: a comparison between Western blotting and receptor binding assays. Brain Res 1995;687:133–142.
Feldman S, Conforti N: Participation of the dorsal hippocampus in the glucocorticoid feedback effect on adrenocortical activity. Neuroendocrinology 1980;30:52–55.
Feldman S, Weidenfeld J: The dorsal hippocampus modifies the negative feedback effect of glucocorticoids on the adrenocortical and median eminence CRF-41 responses to photic stimulation. Brain Res 1993;614:227–232.
Sapolsky RM, Zola-Morgan S, Squire IR: Inhibition of glucocorticoids secretion by the hippocampal formation in the primate. J Neurosci 1991;11:3695–3704.
Miller AH, Spencer RL, Pearce BD, et al: Effects of viral infection on corticosterone secretion and glucocorticoid receptor binding in immune tissues. Psychoneuroendocrinology 1997;22:455–474.
Tonello S, Orti E, De Nicola AF, Rabinow TC, McEwen BS: Regulation of glucocorticoid receptors in brain by corticosterone treatment of adrenalectomized rats. Neuroendocrinology 1982;35:411–417.
Mitchell JB, Rowe W, Boksa P, Meaney MJ: Serotonin regulates type II corticosteroid receptor binding in hippocampal cell cultures. J Neurosci 1990;10:1745–1752.
Tritos N, Kitraki E, Philippidis H, Srylianopoulou F: Neurotransmitter modulation of glucocorticoid receptor mRNA levels in the rat hippocampus. Neuroendocrinology 1999;69:324–330.
Ben-Hur T, Rozenthal J, Itzik A, Weidenfeld J: Rescue of HSV-1 neurovirulence is associated with induction of brain interleukin-1 expression, prostaglandin synthesis and neuroendocrine responses. J. Neurovirol 1996;2:279–278.
Betancur C, Borrell J, Guaza C: Cytokine regulation of corticosteroid receptors in the rat hippocampus: effects of interleukin-1, interleukin-6, tumor necrosis factor and lipopolysaccharide. Neuroendocrinology 1995;62:47–54.
Wohlman A, Yirmiya R, Gallily R, and Weidenfeld J: Effects of Mycoplasma fermentans on brain PGE2: role of glucocorticoids and their receptors. Neuroimmunomodulation 2001;9:141–147.
Oakley RH, Sar M, Cidlowski JA: The human glucocorticoid receptor β isoform. J Boil Chem. 1996;271:9550–9559.
Webster JC, Oakley RH, Jewell CM, Cidlowski JA: Proinflammatory cytokines regulate human glucocorticoid receptor gene expression and lead to the accumulation of the dominant negative β isoform: a mechanism for the generation of glucocorticoid resistance. PNAS 2001;98:6865–6870.
Honda M, Orii F, Ayebe T, Imai S, Ashida T, Obara T Kohogo Y: Expression of glucorticoid receptor beta in lymphocytes of patients with glucocorticoid-resistant ulcerative colitis. Gastroenterology 2000;118:859–866.
Leung DY, Hamid Q, Vottero A, Szefler SJ, et al: Association of glucocorticoid insensitivity with increased expression of glucorticoid receptor beta. J Exp Med 1997;186:1567–1574.
Raison CL, Miller AH: When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003;160:1554–1565.
Yirmiya R: Behavioral and psychological effects of immune activation: implications for ‘depression due to a general medical condition’. Curr Opin Psychiatry 1997;10:470–476.
Yirmiya R: Endotoxin produces a depressive-like episode in rats. Brain Res 1996;711:163–174.
Yirmiya R, Pollak Y, Barak O, Avitsur R, Ovadia H, Bette M, Weihe E, Weidenfeld J: Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001;24:531–544.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.